Source - LSE Regulatory
RNS Number : 7323L
Oncimmune Holdings PLC
11 November 2024
 

For immediate release

 

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")


Director/PDMR Shareholding

 

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company providing research services to the pharmaceutical and biotechnology industries to enable the delivery of precision medicine, announces the acquisition of Subscription Shares by certain board members, and waiver and issue of share options to certain Persons Discharging Managerial Responsibilities pursuant to the Fundraising, as detailed in the Company's announcement dated 18 October 2024 (the "Fundraising Announcement").  A summary of the subscribing Directors' shareholdings are as follows:

 

Subscription for ordinary shares

 

PDMR

Previous holding of Ordinary Shares

Number of Subscription Shares purchased

 

Resultant shareholding

Resulting % of Enlarged Share Capital

Alistair Macdonald

55,555

100,000

155,555

0.14

Martin Gouldstone

36,023

66,667

102,690

0.09

John Goold

1,150,000

333,333

1,483,333

1.33

 

Waiver of options

PDMR

Number of options waived

Date of grant of options waived

 

Exercise price of options waived

Resulting number of options held

Martin Gouldstone

589,971

7 November 2023

£0.1695

0

Martin Hudson

105,263

8 December 2023

£0.266

0

 

Grant of options

PDMR

Number of options granted

Exercise price

 

% of Enlarged Share Capital


Martin Gouldstone

5,588,661

£0.15

5%


Martin Hudson

3,353,197

£0.15

3%


 

The new options are subject to performance conditions relating to the Company's EBITDA and share price performance, further detail of which is set out in the Fundraising Announcement.  

Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the announcement of the Fundraising made by the Company on 18 October 2024.

 

For further information:

 

Oncimmune Holdings plc

contact@oncimmune.com

 

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance) 

Nigel Birks (Life Science Specialist Sales)

Ondraya Swanson (ECM)

+44 (0) 20 7220 0500

 

Zeus (Joint Broker)

Dominic King, Dan Bate

+44 (0)20 3829 5000

 

The notifications set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1. 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Alistair Macdonald

1. 

Reason for the notification

a)

Position/status:

Chairman

b)

Initial notification/Amendment:

Initial notification

2. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Oncimmune Holdings plc

b)

LEI:

213800HCYIWT6YPI1I02

3. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00BYQ94H38

b)

Nature of the transaction:

Purchase of new ordinary shares

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

15.0 pence

100,000

 

d)

Aggregated information:

· Aggregated volume:

· Aggregated Price:

Single transaction as in 3 c) above

e)

Date of the transaction:

23 October 2024

f)

Place of the transaction:

AIM, London Stock Exchange (XLON)

  

1. 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Martin Gouldstone

1. 

Reason for the notification

a)

Position/status:

Chief Executive Officer

b)

Initial notification/Amendment:

Initial notification

2. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Oncimmune Holdings plc

b)

LEI:

213800HCYIWT6YPI1I02

3. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00BYQ94H38

b)

Nature of the transaction:

Purchase of new ordinary shares

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

15.0 pence

66,667

 

d)

Aggregated information:

· Aggregated volume:

· Aggregated Price:

Single transaction as in 3 c) above

e)

Date of the transaction:

23 October 2024

f)

Place of the transaction:

AIM, London Stock Exchange (XLON)

 

1. 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

John Goold

1. 

Reason for the notification

a)

Position/status:

Non-Executive Director

b)

Initial notification/Amendment:

Initial notification

2. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Oncimmune Holdings plc

b)

LEI:

213800HCYIWT6YPI1I02

3. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00BYQ94H38

b)

Nature of the transaction:

Purchase of new ordinary shares

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

15.0 pence

333,333

 

d)

Aggregated information:

· Aggregated volume:

· Aggregated Price:

Single transaction as in 3 c) above

e)

Date of the transaction:

23 October 2024

f)

Place of the transaction:

AIM, London Stock Exchange (XLON)

 

1. 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Martin Gouldstone

1. 

Reason for the notification

a)

Position/status:

Chief Executive Officer

b)

Initial notification/Amendment:

Initial notification

2. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Oncimmune Holdings plc

b)

LEI:

213800HCYIWT6YPI1I02

3. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00BYQ94H38

b)

Nature of the transaction:

Waiver of options

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

16.95 pence

589,971

 

d)

Aggregated information:

· Aggregated volume:

· Aggregated Price:

Single transaction as in 3 c) above

e)

Date of the transaction:

8 November 2024

f)

Place of the transaction:

Outside a trading venue

 

 

1. 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Martin Hudson

1. 

Reason for the notification

a)

Position/status:

Finance Director

b)

Initial notification/Amendment:

Initial notification

2. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Oncimmune Holdings plc

b)

LEI:

213800HCYIWT6YPI1I02

3. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00BYQ94H38

b)

Nature of the transaction:

Waiver of options

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

26.6 pence

105,263

 

d)

Aggregated information:

· Aggregated volume:

· Aggregated Price:

Single transaction as in 3 c) above

e)

Date of the transaction:

8 November 2024

f)

Place of the transaction:

Outside a trading venue

 

1. 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Martin Gouldstone

1. 

Reason for the notification

a)

Position/status:

Chief Executive Officer

b)

Initial notification/Amendment:

Initial notification

2. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Oncimmune Holdings plc

b)

LEI:

213800HCYIWT6YPI1I02

3. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00BYQ94H38

b)

Nature of the transaction:

Grant of options

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

15 pence

5,588,661

 

d)

Aggregated information:

· Aggregated volume:

· Aggregated Price:

Single transaction as in 3 c) above

e)

Date of the transaction:

8 November 2024

f)

Place of the transaction:

Outside a trading venue

 

 

1. 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Martin Hudson

1. 

Reason for the notification

a)

Position/status:

Finance Director

b)

Initial notification/Amendment:

Initial notification

2. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Oncimmune Holdings plc

b)

LEI:

213800HCYIWT6YPI1I02

3. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00BYQ94H38

b)

Nature of the transaction:

Grant of options

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

15 pence

3,353,197

 

d)

Aggregated information:

· Aggregated volume:

· Aggregated Price:

Single transaction as in 3 c) above

e)

Date of the transaction:

8 November 2024

f)

Place of the transaction:

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFFLFFZFLFFBE
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Oncimmune Holdings PLC (ONC)

+0.05p (+0.32%)
delayed 16:35PM